Therefore, modulation of neurotransmitter levels has been suggested as a therapeutic target, as evidenced by the use of serotonin reuptake inhibitors (SSRIs) and acetylcholinesterase inhibitors (AChEIs) for the treatment of cognitive impairment (Recanatini and Valenti, 2004). The gene discussed is ACHE; the disease is Cognitive impairment.